Analysis: Rachel Sachs Rachel Sachs STAT Plus: PhRMA doubles down on R&D but falls short in bid to rein in bad actors
Analysis: Rachel Sachs Rachel Sachs STAT Plus: Prize fund for new antibiotics could mean true innovation
Analysis: Rachel Sachs Rachel Sachs STAT Plus: What the demise of the GOP health care bill means for pharma — and what’s next
